A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: pfnewdosesregimenperformance
  Phrases that lowered it: healthyvolunteersthe pharmacokineticstabletopen label
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 14.8% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 384 (raises risk) · Sponsor's track record
• Sponsor's past trials: 725 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 45 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State NCT00861458 · started 2009 · scored riskier than 2% of active trials completed
• A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers NCT01247883 · started 2010 · scored riskier than 2% of active trials completed
• Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects NCT01012310 · started 2009 · scored riskier than 14% of active trials completed
• Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers NCT01101932 · started 2010 · scored riskier than 23% of active trials completed
• AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects NCT02163161 · started 2014 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.